Women facing difficult-to-treat ovarian cancer have been given renewed hope through the introduction of new drugs, offering a potential breakthrough in treatment options for this challenging disease.
A recent study focusing on ovarian cancer has shown positive outcomes for women with a type of cancer that is traditionally resistant to treatment. Specifically, a combination of avutometinib and defactinib has proven effective in slowing down tumour growth in patients with low-grade serous ovarian cancer.
The results of the clinical trial revealed that nearly a third (31%) of women with this form of ovarian cancer experienced either tumour shrinkage or cessation of tumour growth when treated with the new drug combination. Remarkably, for patients with a mutation in the KRAS gene, the response rate was even more promising, with 44% witnessing tumour shrinkage.
Medical experts are particularly encouraged by these findings as they believe that this innovative treatment approach could revolutionise the management of this specific type of ovarian cancer globally. The hope is that these new drugs could provide a ray of hope for women who have limited or no effective treatment options available to them.
Leading the clinical trial investigating these new drugs is Professor Susana Banerjee, a consultant medical oncologist at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research in London. Professor Banerjee expressed her enthusiasm for the results, stating that the combination of avutometinib and defactinib offers a new standard of care for individuals with recurrent low-grade serous ovarian cancer.
The trial, which is currently in its second phase, has demonstrated lower toxicities for patients compared to conventional treatments, resulting in fewer side effects. As preparations for a phase three trial get underway, there is optimism that the positive outcomes observed thus far will be sustained, leading to improved patient outcomes in the future.
Both avutometinib and defactinib, the investigational drugs used in the trial, work by inhibiting signals that promote the growth of cancer cells. The study showed that most patients were able to tolerate the drugs and any associated side effects, with only a small proportion discontinuing treatment.
Overall, these findings present a promising outlook for women battling low-grade serous ovarian cancer, a rare and aggressive subtype that often poses significant challenges due to its resistance to conventional therapies. By targeting key signalling pathways involved in cancer cell growth, this novel drug combination offers a beacon of hope for patients and may pave the way for improved treatment strategies in the fight against ovarian cancer.